A huge clinical trial is underway to test TXA acid, a drug used in trauma patients, for use in women with postpartum hemorrhage.
The London School of Hygiene and Tropical Medicine (LSHTM), led by chief investigator Professor Ian Roberts, is currently testing the use of “tranexamic (TXA) acid for the treatment of postpartum hemorrhage.” TXA is a “systemic antifribiololytic agent,” meaning it acts to inhibit clot breakdown (fibriololysys), therefore encouraging clotting and decreasing blood loss in incidents of bleeding. Postpartum hemorrhage is a leading cause of obstetric deaths and positive trial results could provide another tool for saving women's lives.